We report successful treatment of cerebral toxoplasmosis in an unrelated donor marrow transplant recipient. The clinical diagnosis was confirmed by polymerase chain reaction (PCR) amplification for T. gondii-DNA performed both on cerebrospinal fluid and blood leukocytes. Retrospective testing of stored blood samples demonstrated positive leukocyte PCR signal detected up to 52 days prior to onset of clinical symptoms. This case highlights the value of PCR in the diagnosis and early detection of cerebral toxoplasmosis. Keywords: toxoplasmosis; cerebral; PCR; marrow transplantation Cerebral toxoplasmosis is a rare and frequently fatal complication of bone marrow transplantation (BMT).
Cerebral toxoplasmosis is a rare and frequently fatal complication of bone marrow transplantation (BMT). 1 Without histologic confirmation, the diagnosis is presumptive and based on suggestive clinical findings, positive serologic tests and typical lesions on neuroradiologic imaging which resolve after appropriate therapy. Definitive diagnosis of this infection requires detection of tachyzoites of Toxoplasma gondii in histologic sections. However, biopsy of the brain may be associated with serious risks, including permanent neurologic damage or death. In immunocompromised hosts, serologic tests are insensitive methods of diagnosis. 2, 3 Polymerase chain reaction (PCR) performed on cerebrospinal fluid (CSF) 4 and blood 5 has been used to diagnose cerebral toxoplasmosis in AIDS patients. We report the diagnosis and, retrospectively, the early detection of toxoplasmosis in a marrow transplant recipient based on positive PCR signal for T. gondii-DNA in CSF and blood leukocytes.
Case report
A 25-year-old man in first complete remission for poor prognosis ALL (WBC at diagnosis 1 100 000/mm 3 , t (4, 11) on chromosomal analysis) underwent matched unrelated donor BMT. The conditioning regimen included total body irradiation, cyclophosphamide and etoposide. Prophylaxis of graft-versus-host disease (GVHD) consisted of shortcourse methotrexate, cyclosporin A and corticosteroids. Neutrophil engraftment was observed on day +15. The post-transplant period was complicated by transient steroidresponsive cutaneous grade II acute GVHD. Trimethoprimsulfamethoxazole (TMP-SMX) was administered twice weekly as prophylaxis against Pneumocystis carinii, but was discontinued on day +65, due to marrow suppression.
The patient presented on day +168 with diplopia. Physical examination revealed isolated left eye upward gaze paralysis. Magnetic resonance imaging (MRI) of the brain showed numerous enhancing lesions involving both cerebral and cerebellar hemispheres (Figure 1 ). Complete blood count showed a WBC of 1900/mm 3 with an absolute neutrophil count of 500/mm 3 . Toxoplasma serology revealed positive IgG titers (7.4 IU/ml) and negative IgM titers (0.23 IU/ml). Pre-transplant recipient and donor T. gondii serostatus were unknown. A lumbar puncture yielded clear CSF with a WBC of 5/mm 3 , of which 24% were neutrophils and 67% lymphocytes. Protein concentration was elevated (77 mg/dl) and glucose was normal (63 mg/dl). Bacterial, fungal and mycobacterial CSF cultures were sterile. Empiric treatment with amphotericin B, pyrimethamine (100 mg daily) and sulfadiazine (4 g daily) was initiated.
Using a multiplex PCR assay that simultaneously detects DNA of T. gondii and Epstein-Barr virus, amplification was carried out as previously described 6 on 1 ml of CSF and on leukocytes obtained from 5 ml of venous blood. Blood leukocytes were isolated by dextran sedimentation. Analysis of PCR products showed a strongly positive signal for T. gondii both in CSF and blood leukocytes (Figure 2 ). Five days after initiation of anti-Toxoplasma therapy, the patient developed progressive ataxia and left-sided weakness. Stereotactic brain biopsy was performed on day +177 to rule out other causes of focal brain lesions. Histological examination of the biopsy specimen revealed necrotic and gliotic brain tissue, and the presence of tachyzoites was shown by immunohistochemical stains (Figure 3) . By day +185, the patient stabilized and a slow but steady improvement was observed thereafter. Therapy with pyrimethamine and sulfadiazine was complicated by chronic anorexia, nau- sea and vomiting. T. gondii-specific amplified bands were not subsequently detected by PCR performed on CSF and blood leukocytes 60 and 90 days after initiation of antiToxoplasma therapy. Six hundred days post transplant, the patient has a Karnofsky performance status of 90%. Ataxia and weakness have resolved completely but diplopia persists. The patient continues to receive pyrimethamine (100 mg daily) and sul- fadiazidine (2 g daily). Serial follow-up MRI scans obtained at 7, 90, 210 and 365 days after initiation of antiToxoplasma therapy showed no significant changes, compared to the scan obtained at diagnosis.
To determine if the PCR test could have contributed to the early diagnosis of toxoplasmosis prior to onset of symptoms, PCR amplification for T. gondii was performed on frozen stored peripheral blood leukocytes that had been obtained weekly for CMV surveillance starting at posttransplant day +30. A positive signal for T. gondii-DNA was detected up to 52 days prior to onset of neurologic symptoms. Notably, the patient acquired a cat 60 days before clinical symptoms of cerebral toxoplasmosis and 8 days before the earliest detectable PCR signal for T. gondii-DNA in stored blood samples.
Discussion
Toxoplasmosis is a rare complication of BMT, which presents with focal brain lesions or with disseminated infection. 2 Reported prevalence in marrow transplant recipients in the USA is 0.3%. 2 Toxoplasma infections usually occur 60-150 days post transplant, and are thought to represent reactivation of latent infection. Occasional cases of toxoplasmosis have been reported in BMT recipients with negative pretransplant Toxoplasma antibody titers, suggesting a transmission of infection via marrow or blood products. 1 In our patient, it is unclear whether the infection was the result of a reactivation, a transplant-related transmission, or a newly acquired infection as this patient adopted a cat 60 days prior to the onset of symptoms.
Although marrow transplant recipients with cerebral toxoplasmosis may respond to specific therapy, poor outcome is uniformly observed due in part to the frequent presence of concurrent GVHD and its immunosuppressive treatment. 2 In our patient, early diagnosis and treatment, and the absence of GVHD at the time cerebral toxoplasmosis developed were probably major contributors to the favorable outcome. Only one other marrow transplant recipient survivor of cerebral toxoplasmosis has been reported. 7 Sensitive and specific non-invasive methods for detection of T. gondii are needed, since invasive procedures in BMT recipients carry a high risk of complications. In AIDS patients with cerebral toxoplasmosis, PCR amplification for T. gondii-DNA in CSF or blood has a high specificity (100%), but a low sensitivity (30-50%). 8, 9 Our case illustrates the usefulness of a positive PCR signal detected in CSF and blood as a rapid diagnostic tool of cerebral toxoplasmosis in a marrow transplant recipient. Two marrow transplant recipients with disseminated toxoplasmosis diagnosed by PCR performed on blood mononuclear cells have been reported; however, in both cases, no cerebral or other specific organ involvement was noted. 10, 11 PCR testing was also used in our patient to retrospectively detect the presence of T. gondii-DNA in blood leukocytes obtained prior to onset of neurologic symptoms. A positive PCR signal for T. gondii-DNA was consistently detected up to 52 days before the onset of diplopia. This observation suggests that detection of a positive PCR signal in blood could be used as an early sign of Toxoplasma infection in allogeneic transplant recipients. Further studies are required to define the sensitivity and specificity of testing blood leukocytes from transplant recipients.
The combination of pyrimethamine and sulfadiazine is a standard regimen in the treatment of toxoplasmosis. Optimal duration of treatment and the role of maintenance therapy in the immunocompromised host have not been determined. In our patient, positive PCR signals for T. gondii-DNA were not detected in either CSF or blood after initiation of anti-Toxoplasma therapy. PCR may be a useful tool to monitor the effect of treatment of cerebral toxoplasmosis in bone marrow transplant recipients.
In summary, this case illustrates that CNS toxoplasmosis can be diagnosed rapidly and non-invasively using PCR from DNA extracted from CSF and blood leukocytes, and that this infection is potentially curable in the setting of BMT. With the lack of other reliable non-invasive diagnostic tests in immunocompromised patients, PCR testing may contribute to early diagnosis and potentially improve the outcome of this frequently fatal infection.
